Second Genome, the San Francisco-based pharmaceutical company working on the ground-breaking drug known as SGM-1019, began research four years ago with an exclusive focus on microbiomes, the generic name for the 100 trillion bacteria humans host in their bodies.
Microbiomes are believed to play a bigger part than previously expected in the body system, with a delicate balance that, when upset, can trigger certain inflammations and diseases.
Through SGM-1019, researchers hope to inhibit a target that triggers inflammatory bowel disease in intestines.
By Ruchi Singh
reporter
Park Sae-jin
swatchsjp@ajunews.com
